Human fibronectin extra domain B as a biomarker for targeted therapy in cancer

Relinde I. Y. Lieverse; Damienne Marcus; Alexander M. A. van der Wiel; Evert J. Van Limbergen; Jan Theys; Ala Yaromina; Philippe Lambin; Ludwig J. Dubois

doi:10.1002/1878-0261.12705

Human fibronectin extra domain B as a biomarker for targeted therapy in cancer

Relinde I. Y. Lieverse, Damienne Marcus, Alexander M. A. van der Wiel, Evert J. Van Limbergen, Jan Theys, Ala Yaromina, Philippe Lambin, Ludwig J. Dubois^*

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

The extracellular matrix protein fibronectin contains a domain that is rarely found in healthy adults and is almost exclusively expressed by newly formed blood vessels in tumours, particularly in solid tumours, different types of lymphoma and some leukaemias. This domain, called the extra domain B (ED-B), thus has broad therapeutic potential. The antibody L19 has been developed to specifically target ED-B and has shown therapeutic potential when combined with cytokines, such as IL-2. In this review article, we discuss the preclinical research and clinical trials that highlight the potential of ED-B targeting for the imaging and treatment of various types of cancer. ED-B-centred studies also highlight how proper patient stratification is of utmost importance for the successful implementation of novel antibody-based targeted therapies.

Original language	English
Pages (from-to)	1555-1568
Number of pages	14
Journal	Molecular oncology
Volume	14
Issue number	7
DOIs	https://doi.org/10.1002/1878-0261.12705
Publication status	Published - Jul 2020

Keywords

angiogenesis
biomarker
cancer
extra domain B
immunotherapy
targeted therapy
FUSION PROTEIN L19-TNF
IMMUNOCYTOKINE L19-IL2
PROSTATE-CANCER
CELLULAR FIBRONECTIN
RECOMBINANT ANTIBODY
METASTATIC MELANOMA
RISK-STRATIFICATION
TUMOR VASCULATURE
INTERFERON-GAMMA
TISSUE FACTOR

Access to Document

10.1002/1878-0261.12705Licence: CC BY

Cite this

@article{c7d6df1472fe4068b5fb646dd7ff329c,

title = "Human fibronectin extra domain B as a biomarker for targeted therapy in cancer",

abstract = "The extracellular matrix protein fibronectin contains a domain that is rarely found in healthy adults and is almost exclusively expressed by newly formed blood vessels in tumours, particularly in solid tumours, different types of lymphoma and some leukaemias. This domain, called the extra domain B (ED-B), thus has broad therapeutic potential. The antibody L19 has been developed to specifically target ED-B and has shown therapeutic potential when combined with cytokines, such as IL-2. In this review article, we discuss the preclinical research and clinical trials that highlight the potential of ED-B targeting for the imaging and treatment of various types of cancer. ED-B-centred studies also highlight how proper patient stratification is of utmost importance for the successful implementation of novel antibody-based targeted therapies.",

keywords = "angiogenesis, biomarker, cancer, extra domain B, immunotherapy, targeted therapy, FUSION PROTEIN L19-TNF, IMMUNOCYTOKINE L19-IL2, PROSTATE-CANCER, CELLULAR FIBRONECTIN, RECOMBINANT ANTIBODY, METASTATIC MELANOMA, RISK-STRATIFICATION, TUMOR VASCULATURE, INTERFERON-GAMMA, TISSUE FACTOR",

author = "Lieverse, {Relinde I. Y.} and Damienne Marcus and {van der Wiel}, {Alexander M. A.} and {Van Limbergen}, {Evert J.} and Jan Theys and Ala Yaromina and Philippe Lambin and Dubois, {Ludwig J.}",

note = "Funding Information: This work was financially supported from the ERC Advanced Grant (ERC‐ADG‐2015, no. 694812 – HYPOXIMMUNO), the European Program H2020‐2017 grant (ImmunoSABR – no. 733008) and the European Union's H2020 Research and Innovation Program Marie Sklodowska‐Curie International Training Network (H2020‐MSCA‐ITN) grant (RADIATE – no. 642623). Funding Information: This work was financially supported from the ERC Advanced Grant (ERC-ADG-2015, no. 694812 – HYPOXIMMUNO), the European Program H2020-2017 grant (ImmunoSABR – no. 733008) and the European Union's H2020 Research and Innovation Program Marie Sklodowska-Curie International Training Network (H2020-MSCA-ITN) grant (RADIATE – no. 642623). Publisher Copyright: {\textcopyright} 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.",

year = "2020",

month = jul,

doi = "10.1002/1878-0261.12705",

language = "English",

volume = "14",

pages = "1555--1568",

journal = "Molecular oncology",

issn = "1574-7891",

publisher = "Elsevier",

number = "7",

}

TY - JOUR

T1 - Human fibronectin extra domain B as a biomarker for targeted therapy in cancer

AU - Lieverse, Relinde I. Y.

AU - Marcus, Damienne

AU - van der Wiel, Alexander M. A.

AU - Van Limbergen, Evert J.

AU - Theys, Jan

AU - Yaromina, Ala

AU - Lambin, Philippe

AU - Dubois, Ludwig J.

N1 - Funding Information: This work was financially supported from the ERC Advanced Grant (ERC‐ADG‐2015, no. 694812 – HYPOXIMMUNO), the European Program H2020‐2017 grant (ImmunoSABR – no. 733008) and the European Union's H2020 Research and Innovation Program Marie Sklodowska‐Curie International Training Network (H2020‐MSCA‐ITN) grant (RADIATE – no. 642623). Funding Information: This work was financially supported from the ERC Advanced Grant (ERC-ADG-2015, no. 694812 – HYPOXIMMUNO), the European Program H2020-2017 grant (ImmunoSABR – no. 733008) and the European Union's H2020 Research and Innovation Program Marie Sklodowska-Curie International Training Network (H2020-MSCA-ITN) grant (RADIATE – no. 642623). Publisher Copyright: © 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

PY - 2020/7

Y1 - 2020/7

N2 - The extracellular matrix protein fibronectin contains a domain that is rarely found in healthy adults and is almost exclusively expressed by newly formed blood vessels in tumours, particularly in solid tumours, different types of lymphoma and some leukaemias. This domain, called the extra domain B (ED-B), thus has broad therapeutic potential. The antibody L19 has been developed to specifically target ED-B and has shown therapeutic potential when combined with cytokines, such as IL-2. In this review article, we discuss the preclinical research and clinical trials that highlight the potential of ED-B targeting for the imaging and treatment of various types of cancer. ED-B-centred studies also highlight how proper patient stratification is of utmost importance for the successful implementation of novel antibody-based targeted therapies.

AB - The extracellular matrix protein fibronectin contains a domain that is rarely found in healthy adults and is almost exclusively expressed by newly formed blood vessels in tumours, particularly in solid tumours, different types of lymphoma and some leukaemias. This domain, called the extra domain B (ED-B), thus has broad therapeutic potential. The antibody L19 has been developed to specifically target ED-B and has shown therapeutic potential when combined with cytokines, such as IL-2. In this review article, we discuss the preclinical research and clinical trials that highlight the potential of ED-B targeting for the imaging and treatment of various types of cancer. ED-B-centred studies also highlight how proper patient stratification is of utmost importance for the successful implementation of novel antibody-based targeted therapies.

KW - angiogenesis

KW - biomarker

KW - cancer

KW - extra domain B

KW - immunotherapy

KW - targeted therapy

KW - FUSION PROTEIN L19-TNF

KW - IMMUNOCYTOKINE L19-IL2

KW - PROSTATE-CANCER

KW - CELLULAR FIBRONECTIN

KW - RECOMBINANT ANTIBODY

KW - METASTATIC MELANOMA

KW - RISK-STRATIFICATION

KW - TUMOR VASCULATURE

KW - INTERFERON-GAMMA

KW - TISSUE FACTOR

U2 - 10.1002/1878-0261.12705

DO - 10.1002/1878-0261.12705

M3 - (Systematic) Review article

C2 - 32386436

SN - 1574-7891

VL - 14

SP - 1555

EP - 1568

JO - Molecular oncology

JF - Molecular oncology

IS - 7

ER -